ClinicalTrialStartPulse: Phase 2, page 2 of 4
Records 51 to 200 of the 500 newest listed for this hub. Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
| Record | Phase | Conditions | Enrollment |
|---|---|---|---|
| GlaxoSmithKline | Phase 2 | Primary Myelofibrosis | 237 |
| RemeGen Co., Ltd. | Phase 2 | Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy | 412 |
| Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | Pancreatic Cancer | 140 |
| Hoffmann-La Roche | Phase 2 | Urothelial Cancer | 204 |
| Rapport Therapeutics Inc. | Phase 2 | Bipolar 1 Disorder | 253 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 | Herpes Zoster | 496 |
| Sunshine Lake Pharma Co., Ltd. | Phase 2 | Chemotherapy-induced Anemia; Non-Myeloid Malignancy | 160 |
| Keymed Biosciences Co.Ltd | Phase 2 | Advanced Solid Tumors | 128 |
| AstraZeneca | Phase 2 | Overweight and Obesity | 166 |
| Pfizer | Phase 2 | Atopic Dermatitis | 507 |
| 4Moving Biotech | Phase 2 | Knee Osteoarthritis; Synovitis of Knee | 130 |
| ModernaTX, Inc. | Phase 2 | Norovirus Acute Gastroenteritis | 1407 |
| Idorsia Pharmaceuticals Ltd. | Phase 2 | Non-Segmental Vitiligo | 30 |
| Atom Therapeutics Co., Ltd | Phase 2 | Chronic Kidney Disease | 80 |
| Merck Sharp & Dohme LLC | Phase 2 | Malignant Neoplasm | 15 |
| Puma Biotechnology, Inc. | Phase 2 | Small Cell Lung Cancer ( SCLC ) | 50 |
| Prana Therapies Inc | Phase 2 | Atopic Dermatitis (AD) | 39 |
| BeOne Medicines | Phase 2 | Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma | 30 |
| AiCuris Anti-infective Cures AG | Phase 2 | BK Virus Infection; BKV Infection; Kidney Transplant | 24 |
| Bristol-Myers Squibb | Phase 2 | Arthritis, Rheumatoid | 84 |
| Hansoh BioMedical R&D Company | Phase 2 | Non-Small Cell Lung Cancer | 76 |
| Janssen Research & Development, LLC | Phase 2 | Carcinoma, Non-Small-Cell Lung | 71 |
| Janssen Research & Development, LLC | Phase 2 | Multiple Myeloma | 43 |
| Janssen Pharmaceutica N.V., Belgium | Phase 2 | Alzheimer Disease | 55 |
| Janssen Research & Development, LLC | Phase 2 | Multiple Myeloma | 11 |
| Janssen Research & Development, LLC | Phase 2 | Carcinoma, Non-Small-Cell Lung | 57 |
| Grünenthal GmbH | Phase 2 | Duchenne Muscular Dystrophy (DMD) | 36 |
| Beijing Mabworks Biotech Co., Ltd. | Phase 2 | Multiple Myeloma | 78 |
| Antev Ltd. | Phase 2 | Endometriosis Pelvic; Endometriosis Ovaries; Premenopausal; Endometriosis (Diagnosis); Dysmenorrhoea; Dyspareunia (Female) | 84 |
| Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Phase 2 | Advanced Solid Tumors | 63 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Phase 2 | Pulmonary Disease, Chronic Obstructive, COPD | 70 |
| Crescent Biopharma, Inc. | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M); Gastric/GEJ; Biliary Tract Cancer (BTC); Esophageal Squamous Cell Carcinoma (ESCC); Ovarian Cancer; Endometrial Cancer | 219 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | 75 |
| Cristcot LLC | Phase 2 | Hemorrhoidal Disease | 78 |
| Arsenal Biosciences, Inc. | Phase 2 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma; Recurrence | 37 |
| Alexion Pharmaceuticals, Inc. | Phase 2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 78 |
| GlaxoSmithKline | Phase 2 | Carcinoma | 41 |
| Hoffmann-La Roche | Phase 2 | Breast Cancer | 83 |
| Qlaris Bio, Inc. | Phase 2 | Non-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (NTG) | 9 |
| Aperta Biosciences, LLC | Phase 2 | Blepharitis | 15 |
| X4 Pharmaceuticals | Phase 2 | Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders; Chronic Neutropenia; Autoimmune Neutropenia; Chronic Idiopathic Neutropenia | 40 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | 75 |
| Suzhou HepaThera Biotech Co., Ltd. | Phase 2 | Chronic Hepatitis B | 86 |
| AstraZeneca | Phase 2 | ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC) | 55 |
| Alkermes, Inc. | Phase 2 | Major Depressive Disorder (MDD) | 180 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 2 | Asthma | 160 |
| Sanofi | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps | 71 |
| EIP Pharma Inc | Phase 2 | Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke | 45 |
| T-MAXIMUM Pharmaceutical Inc | Phase 2 | Brain Metastases From Solid Tumors | 40 |
| Medsyn Biopharma, LLC | Phase 2 | Triple-Negative Breast Cancer (TNBC); Gastric Cancer (GC); Gastric Cancer Adenocarcinoma Metastatic; Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent; Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | 75 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | IgA Nephropathy | 56 |
| Aperta Biosciences, LLC | Phase 2 | Blepharitis | 66 |
| Changchun BCHT Biotechnology Co. | Phase 2 | Pertussis (Whooping Cough); Diphtheria; Tetanus | 420 |
| AbbVie | Phase 2 | Extensive Stage-Small Cell Lung Cancer | 80 |
| Merck Sharp & Dohme LLC | Phase 2 | Rheumatoid Arthritis | 60 |
| Editas Medicine, Inc. | Phase 2 | Heterozygous Familial Hypercholesterolemia (HeFH) | 56 |
| Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Phase 2 | Atopic Dermatitis (AD) | 160 |
| Healthgen Biotechnology Corp. | Phase 2 | Gastric Mucosal Lesion | 40 |
| AbbVie | Phase 2 | Extensive Stage-Small Cell Lung Cancer (ES-SCLC) | 80 |
| McNeil AB | Phase 2 | Smoking Cessation; Nicotine Replacements Therapy | 280 |
| Hikma Pharmaceuticals USA Inc. | Phase 2 | Epinephrine; Hypersensitivity, Immediate; Anaphylaxis | 44 |
| Danisco | Phase 2 | Digestive Symptoms; Gastrointestinal Symptoms; Healthy; Impaired Pancreatic Function | 50 |
| AN2 Therapeutics, Inc | Phase 2 | Polycythemia Vera (SNOMED CT: 109992005) | 75 |
| Ipsen | Phase 2 | Primary Sclerosing Cholangitis | 68 |
| Ultragenyx Pharmaceutical Inc | Phase 2 | Angelman Syndrome | 55 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Tuberculosis | 144 |
| Pfizer | Phase 2 | Pulmonary Hypertension | 42 |
| Genmab | Phase 2 | Lung Cancer - Non Small Cell Squamous; Lung Cancer - Non Small Cell Non-Squamous | |
| National Cancer Institute (NCI) | Phase 2 | Core Binding Factor Acute Myeloid Leukemia | 162 |
| National Cancer Institute (NCI) | Phase 2 | Acute Myeloid Leukemia | 126 |
| Mclean Hospital | Phase 2 | Major Depression; Healthy Participants | 100 |
| West China Hospital | Phase 2 | Radiation-induced Dermatitis | 140 |
| Northwestern University | Phase 2 | Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma | 125 |
| Icahn School of Medicine at Mount Sinai | Phase 2 | Post-acute Sequelae of COVID-19; Long COVID | 150 |
| Swiss Cancer Institute | Phase 2 | Melanoma; Advanced Melanoma | 108 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Atopic Dermatitis | 18 |
| Pfizer | Phase 2 | Breast Cancer | 20 |
| Pfizer | Phase 2 | Breast Cancer | 11 |
| University of Texas Southwestern Medical Center | Phase 2 | Methamphetamine Use Disorder | 228 |
| Virginia Commonwealth University | Phase 2 | Breast Cancer | 134 |
| National Cancer Institute (NCI) | Phase 2 | Prostate Neoplasms; Prostatic Cancer; Prostate Cancer; Cancer Of Prostate; Metastatic Prostate Cancer | 385 |
| National Cancer Institute (NCI) | Phase 2 | Colorectal Neoplasms; Breast Neoplasms | 268 |
| Metagen Therapeutics, Inc. | Phase 2 | Ulcerative Colitis (UC); Ulcerative Colitis, Active Moderate | 54 |
| Arjil Pharmaceuticals LLC | Phase 2 | Dermatitis Atopic | 40 |
| Masonic Cancer Center, University of Minnesota | Phase 2 | Mucopolysaccharidosis Disorders; Hurler Syndrome; Hunter Syndrome; Maroteaux Lamy Syndrome; Sly Syndrome; Alpha-Mannosidosis | 149 |
| M.D. Anderson Cancer Center | Phase 2 | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia | 129 |
| National Cancer Institute (NCI) | Phase 2 | Peripheral T-cell Lymphomas; Lymphoproliferative Disorders; Immune System Diseases | 118 |
| National Institutes of Health Clinical Center (CC) | Phase 2 | Hemochromatosis | 622 |
| Jiangsu Jingze Biopharmaceutical Co., Ltd. | Phase 2 | Vitreomacular Traction (VMT) | 48 |
| NYU Langone Health | Phase 2 | Early-stage Breast Cancer; Fear of Cancer Recurrence; Anxiety; Depression | 100 |
| University of Arkansas | Phase 2 | Chronic Kidney Disease (CKD) | 230 |
| Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Phase 2 | Dyslipidemia | 160 |
| Henan Cancer Hospital | Phase 2 | Locally Advanced Resectable Rectal Cancer | 155 |
| Juro Sciences Inc. | Phase 2 | Participants With Underactive Bladder (UAB) | 70 |
| Beni-Suef University | Phase 2 | Iron Deficiency Anemia (IDA); ESRD (End Stage Renal Disease) | 108 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Electric Stimulation Therapy; Obesity; Weight Loss; Eating | 126 |
| George Washington University | Phase 2 | Obesity & Overweight; Respiratory Depression; Intranasal Drug Administration; Oxytocin; Bariatric Surgery | 100 |
| Beijing Tiantan Hospital | Phase 2 | Brain Neoplasms; Sleep Initiation and Maintenance Disorders | 112 |
| Cytogel Pharma, LLC | Phase 2 | Acute Postoperative Pain; Dental Pain | 32 |
| Sun Yat-sen University | Phase 2 | Nasopharyngeal Cancinoma (NPC) | 214 |
| Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | Phase 2 | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | 384 |
| VA Office of Research and Development | Phase 2 | PTSD - Post Traumatic Stress Disorder | 138 |
| Beijing Tiantan Hospital | Phase 2 | Parkinson Disease (PD); Sleep Initiation and Maintenance Disorders; Deep Brain Stimulation | 128 |
| International AIDS Vaccine Initiative | Phase 2 | Tuberculosis (TB) | 5531 |
| Washington University School of Medicine | Phase 2 | Acute Myeloid Leukemia | 107 |
| Tanta University | Phase 2 | Rheumatoid Arthritis (RA | 100 |
| National Institute of Unani Medicine, Bengaluru | Phase 2 | MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) | 128 |
| Al-Azhar University | Phase 2 | No Reflow Phenomenon; Reperfusion Injuries, Myocardial; Myocardial Infarction; STEMI - ST Elevation Myocardial Infarction; Coronary Artery Disease (CAD); PCI | 100 |
| GuangZhou Cellgenes Biotechnology Co., Ltd. | Phase 2 | Ischemic Stroke or High-risk TIA (ABCD² ≥ 4) | 87 |
| Menoufia University | Phase 2 | Post Operative Analgesia | 152 |
| University of Texas Southwestern Medical Center | Phase 2 | Substance Use Disorders; Substance Use; Methamphetamine Abuse | 120 |
| Case Western Reserve University | Phase 2 | HIV/AIDS; Lipohypertrophy; Obesity | 108 |
| VA Office of Research and Development | Phase 2 | Major Depression | 150 |
| University Health Network, Toronto | Phase 2 | Glottic Carcinoma | 150 |
| AeroRx Therapeutics Inc. | Phase 2 | COPD; Chronic Obstructive Pulmonary Disease (COPD); Lung Disease Chronic; Lung Diseases, Obstructive | 64 |
| University of Alberta | Phase 2 | Low Back Pain | 713 |
| University of Miami | Phase 2 | Glaucoma | 100 |
| Tongji Hospital | Phase 2 | Cervical Intraepithelial Neoplasia Grade 3 | 260 |
| University of Mississippi Medical Center | Phase 2 | Viral Diseases | 250 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Invasive Breast Cancer | 200 |
| University of Miami | Phase 2 | Kidney Cancer; Renal Cancer; Renal Neoplasm | 137 |
| Astellas Pharma Global Development, Inc. | Phase 2 | Glaucoma | 156 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 | Limited-stage Small-cell Lung Cancer | 120 |
| LigaChem Biosciences, Inc. | Phase 2 | Advanced Solid Tumors | 191 |
| Nanjing Leads Biolabs Co.,Ltd | Phase 2 | Metastatic Colorectal Carcinoma | 369 |
| Merck Sharp & Dohme LLC | Phase 2 | Advanced Solid Tumors; Malignant Neoplasm | 200 |
| Beijing Sungen Biomedical Technology Co., Ltd | Phase 2 | Acute Pancreatitis | 129 |
| BrYet US, Inc. | Phase 2 | Advanced Solid Tumor With Lung and/or Liver Involvement | 108 |
| Hutchmed | Phase 2 | Solid Tumor, Adult | 147 |
| XYone Therapeutics, Inc | Phase 2 | MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; GEJ Adenocarcinoma; Colorectal Cancer; Pancreatic Adenocarcinoma | 190 |
| Biothervax SpA | Phase 2 | Respiratory Syncytial Virus Infection Prevention; Tuberculosis Prevention | 200 |
| Medicines Development for Global Health | Phase 2 | Erythema Nodosum Leprosum | 45 |
| Children's Hospital Medical Center, Cincinnati | Phase 2 | Allogeneic Stem Cell Transplantation | 256 |
| Johns Hopkins University | Phase 2 | Mood (Psychological Function); Well Being; Mood; Healthy | 20 |
| National Human Genome Research Institute (NHGRI) | Phase 2 | Focal Segmental Glomerulosclerosis; Minimal Change Disease; Membranous Nephropathy | 30 |
| Tanta University | Phase 2 | SBP - Spontaneous Bacterial Peritonitis | 60 |
| Tanta University | Phase 2 | SBP - Spontaneous Bacterial Peritonitis | 60 |
| National Cancer Institute (NCI) | Phase 2 | Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma | 87 |
| City of Hope Medical Center | Phase 2 | Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma; Gastric Mucosa-Associated Lymphoid Tissue Lymphoma; Marginal Zone Lymphoma; Nodal Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Lymphoma | 35 |
| University Health Network, Toronto | Phase 2 | Triple-Negative Breast Cancer (TNBC) | 60 |
| Swiss Cancer Institute | Phase 2 | B-cell Lymphoma | 92 |
| Columbia University | Phase 2 | Hypernatremia | 80 |
| Eli Lilly and Company | Phase 2 | Obesity; Overweight | 460 |
| Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd. | Phase 2 | sHTG; HTG With ASCVD (Diagnosed or at Increased Risk) | 192 |
| Beijing Keymed Biosciences Co., Ltd. | Phase 2 | Perennial Allergic Rhinitis (PAR) | 200 |
| SPH Sine Pharmaceutical Laboratories Co., Ltd. | Phase 2 | Bacterial Vaginosis (BV) | 150 |
| EMD Serono Research & Development Institute, Inc. | Phase 2 | Solid Tumors; Gastric Cancer; Non-Small Cell Lung Cancer (NSCLC); Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma (PDAC) | 184 |
| Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP) | 120 |
| Bausch & Lomb Incorporated | Phase 2 | Pain, Postoperative | 130 |
| BioNTech SE | Phase 2 | Advanced Solid Tumors | 173 |
All ClinicalTrialStartPulse record reports